All lobbying filings

MARSHALL & POPP, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Biopharmaceutical industry trade association.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $40,000.00 income · posted Apr 17, 2026

Official filing document

Bills named in this filing 4

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 7148
Consolidated Appropriations Act, 2026
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act

Lobbying activity 3

Pharmacy

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

Trade (domestic/foreign)

Issues related to tariff and trade policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.